Hofseth BioCare ASA
HOFBF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $257 | $195 | $120 | $88 |
| % Growth | 32.1% | 61.8% | 37.5% | – |
| Cost of Goods Sold | $170 | $151 | $92 | $65 |
| Gross Profit | $88 | $44 | $29 | $23 |
| % Margin | 34.1% | 22.7% | 23.7% | 26.4% |
| R&D Expenses | $0 | $11 | $14 | $13 |
| G&A Expenses | $28 | $22 | $18 | $32 |
| SG&A Expenses | $43 | $35 | $33 | $45 |
| Sales & Mktg Exp. | $15 | $13 | $15 | $13 |
| Other Operating Expenses | $158 | $70 | $2 | $0 |
| Operating Expenses | $201 | $147 | $157 | $142 |
| Operating Income | -$113 | -$103 | -$129 | -$119 |
| % Margin | -44% | -52.6% | -106.8% | -135.3% |
| Other Income/Exp. Net | -$10 | -$4 | -$9 | -$8 |
| Pre-Tax Income | -$123 | -$107 | -$137 | -$126 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$123 | -$107 | -$137 | -$126 |
| % Margin | -47.9% | -54.7% | -114.1% | -144.3% |
| EPS | -0.3 | -0.27 | -0.37 | -0.35 |
| % Growth | -11.1% | 27% | -5.7% | – |
| EPS Diluted | -0.3 | -0.27 | -0.37 | -0.35 |
| Weighted Avg Shares Out | 411 | 395 | 375 | 358 |
| Weighted Avg Shares Out Dil | 412 | 395 | 375 | 358 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $1 | $1 |
| Interest Expense | $16 | $8 | $10 | $9 |
| Depreciation & Amortization | $40 | $36 | $30 | $29 |
| EBITDA | -$68 | -$63 | -$97 | -$88 |
| % Margin | -26.4% | -32.2% | -80.5% | -100.1% |